MATCHPOINT: MAnagement of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a dose-finding study

Trial Overview and Summary

The aim of this trial is to find a safe and effective dose of a drug called Ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase. Ponatinib is a Tyrosine Kinase Inhibitor (TKI) and TKIs stop enzymes called Tyrosine Kinases from working. By stopping these enzymes from working, the normal signals within the cells are disrupted. TKIs are often used in the treatment of cancers including leukaemia such as CML. 30 patients from the United Kingdom will be invited to take part in this trial.

Trial summary document [.pdf]

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Professor Mhairi Copland
Sponsor: University of Birmingham
Funders: Bloodwise, as part of their Trials Acceleration Programme (TAP) and Ariad Pharmaceuticals Inc.
Disease Site: Chronic myeloid leukaemia
Trial Type: Clinical Trial of an Investigational Medicinal Product
Status: Closed to recruitment, in follow up
UKCRN Study ID: 15879
Open to new sites? No  
Recruitment start date: 02-Dec-2014
Recruitment end date: 26-Apr-2018
CRCTU Trial Management Team: Haematology
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website. [opens new page]


More information

Cancer Help (Cancer Research UK) MATCHPOINT trial [opens new page]